相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Serum interferon-α levels and IFN type I-stimulated genes score perform equally to assess systemic lupus erythematosus disease activity
Francois Chasset et al.
ANNALS OF THE RHEUMATIC DISEASES (2022)
B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial
Richard A. Furie et al.
ANNALS OF THE RHEUMATIC DISEASES (2022)
Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis
David Jayne et al.
ANNALS OF THE RHEUMATIC DISEASES (2022)
Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials
Eric F. Morand et al.
LANCET RHEUMATOLOGY (2022)
Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials
Ian N. Bruce et al.
ANNALS OF THE RHEUMATIC DISEASES (2022)
TLR7 gain-of-function genetic variation causes human lupus
Grant J. Brown et al.
NATURE (2022)
Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study
Victoria P. Werth et al.
RHEUMATOLOGY (2022)
Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus
Joan T. Merrill et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus
Richard A. Furie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Practical management of patients on hydroxychloroquine
Christophe Richez et al.
JOINT BONE SPINE (2021)
Experience with milatuzumab, an anti-CD74 antibody against immunomodulatory macrophage migration inhibitory factor (MIF) receptor, for systemic lupus erythematosus (SLE)
Daniel J. Wallace et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Interleukin-2 and regulatory T cells in rheumatic diseases
Antonios G. A. Kolios et al.
NATURE REVIEWS RHEUMATOLOGY (2021)
Hydroxychloroquine in systemic and autoimmune diseases: Where are we now?
Alina Dima et al.
JOINT BONE SPINE (2021)
Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus
Richard A. Furie et al.
RHEUMATOLOGY (2021)
GENERATION OF PT101, A HIGHLY SELECTIVE IL-2 MUTEIN FOR TREATMENT OF AUTOIMMUNE DISEASES
J. Visweswaraiah et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Depleting plasmacytoid dendritic cells reduces local type I interferon responses and disease activity in patients with cutaneous lupus
Jodi L. Karnell et al.
SCIENCE TRANSLATIONAL MEDICINE (2021)
Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials
Raj Tummala et al.
LUPUS SCIENCE & MEDICINE (2021)
T-cell expression of Bruton's tyrosine kinase promotes autoreactive T-cell activation and exacerbates aplastic anemia
Simo Xia et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2020)
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
Eric F. Morand et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial
Hermine Brunner et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Targeting CD38 with Daratumumab in Refractory Systemic Lupus Erythematosus
Lennard Ostendorf et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis
Richard Furie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Receptor-gated IL-2 delivery by an anti-human IL-2 antibody activates regulatory T cells in three different species
Ufuk Karakus et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Shared development of targeted therapies among autoimmune and inflammatory diseases: a systematic repurposing analysis
Arthur Petitdemange et al.
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE (2020)
Phoenix from the flames: Rediscovering the role of the CD40-CD40L pathway in systemic lupus erythematosus and lupus nephritis
Meera Ramanujam et al.
AUTOIMMUNITY REVIEWS (2020)
Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus
Richard Furie et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
2019 update of the EULAR recommendations for the management of systemic lupus erythematosus
Antonis Fanouriakis et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
The essential role of costimulatory molecules in systemic lupus erythematosus
Z. X. Xiao et al.
LUPUS (2019)
Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date
Renaud Felten et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2019)
Type I interferon gene signature test-low and -high patients with systemic lupus erythematosus have distinct gene expression signatures
P. Z. Brohawn et al.
LUPUS (2019)
Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial
Michelle Rosenzwajg et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
10 most important contemporary challenges in the management of SLE
Renaud Felten et al.
LUPUS SCIENCE & MEDICINE (2019)
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1) a randomised, controlled, phase 3 trial
Richard A. Furie et al.
LANCET RHEUMATOLOGY (2019)
Interferon pathway in SLE: one key to unlocking the mystery of the disease
Lars Ronnblom et al.
LUPUS SCIENCE & MEDICINE (2019)
The 2018 pipeline of targeted therapies under clinical development for Systemic Lupus Erythematosus: a systematic review of trials
Renaud Felten et al.
AUTOIMMUNITY REVIEWS (2018)
A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease
Laurence B. Peterson et al.
JOURNAL OF AUTOIMMUNITY (2018)
Defective BTLA functionality is rescued by restoring lipid metabolism in lupus CD4+ T cells
Matthieu Sawaf et al.
JCI INSIGHT (2018)
Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus
Richard Furie et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Bruton's Tyrosine Kinase: An Emerging Key Player in Innate Immunity
Alexander N. R. Weber et al.
FRONTIERS IN IMMUNOLOGY (2017)
Engagement of SLAMF3 enhances CD4+ T-cell sensitivity to IL-2 and favors regulatory T-cell polarization in systemic lupus erythematosus
Denis Comte et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus
Tobias Alexander et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Anti-BDCA2 monoclonal antibody inhibits plasmacytoid dendritic cell activation through Fc-dependent and Fc-independent mechanisms
Alex Pellerin et al.
EMBO MOLECULAR MEDICINE (2015)
Type I interferons in infectious disease
Finlay McNab et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Efficacy and Safety of Abatacept in Lupus Nephritis A Twelve-Month, Randomized, Double-Blind Study
Richard Furie et al.
ARTHRITIS & RHEUMATOLOGY (2014)
Treatment of Lupus Nephritis With Abatacept
Anca D. Askanase et al.
ARTHRITIS & RHEUMATOLOGY (2014)
Efficacy and Safety of Ocrelizumab in Active Proliferative Lupus Nephritis: Results From a Randomized, Double-Blind, Phase III Study
Eduardo F. Mysler et al.
ARTHRITIS AND RHEUMATISM (2013)
Costimulatory Pathways: Physiology and Potential Therapeutic Manipulation in Systemic Lupus Erythematosus
Nien Yee Kow et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2013)
Efficacy and Safety of Rituximab in Patients With Active Proliferative Lupus Nephritis The Lupus Nephritis Assessment With Rituximab Study
Brad H. Rovin et al.
ARTHRITIS AND RHEUMATISM (2012)
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
Richard Furie et al.
ARTHRITIS AND RHEUMATISM (2011)
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial
Sandra V. Navarra et al.
LANCET (2011)
The Efficacy and Safety of Abatacept in Patients With Non-Life-Threatening Manifestations of Systemic Lupus Erythematosus Results of a Twelve-Month, Multicenter, Exploratory, Phase IIb, Randomized, Double-Blind, Placebo-Controlled Trial
J. T. Merrill et al.
ARTHRITIS AND RHEUMATISM (2010)
Efficacy and Safety of Rituximab in Moderately-to-Severely Active Systemic Lupus Erythematosus The Randomized, Double-Blind, Phase II/III Systemic Lupus Erythematosus Evaluation of Rituximab Trial
Joan T. Merrill et al.
ARTHRITIS AND RHEUMATISM (2010)
Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus
EC Baechler et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
分享论文
